Eisai Co., Ltd.
FY2026 Q1 Consolidated IFRS Financial Results
Revenue for FY2026 Q1 was 234.3 billion yen, with full-year guidance of 883.5 billion yen and progress of 26.5%. Growth driven by the pharmaceutical business, with contributions from key products such as Lenivima, Lequenbi, and Deebigo. Considering exchange rate impact and restructuring-related costs. Core operating profit of 24.7 billion yen, with a full-year target of 70.0 billion yen.
Key Figures
- Sales Revenue 2,343 (billion yen) / Progress 26.5%
- Full-year Forecast 8,835 (billion yen) / Sales share 100.0%
- Core Operating Profit 247 (billion yen) / Progress 35.3%
AI要約
Financial Performance Overview
Eisai reported FY2026 Q1 net sales of 23.43 billion yen (1Q actual, full-year forecast 88.35 billion yen, progress 26.5%). Growth driven by the pharmaceutical business, with contributions from flagship products Lenvim, Lekenbi, and Deebigo. Selling, general and administrative expenses and R&D costs increased, but core operating profit remained solid. Currency effects contributed to sales and profits to a degree. Certain severance-related costs associated with a business restructuring were partially recognized.
Outlook and Investor Impact
Full-year FY2026 sales forecast of 883.5 billion yen, progress 26.5%, and core operating profit of 70.0 billion yen are anticipated. Steady growth in key product lines and progress of new development products are expected to support performance. However, ongoing currency fluctuations and continued increases in R&D investment may impact margins. Monitor quarterly trends and approvals/sales developments of major development candidates going forward.
Sales Revenue Trend
Operating Profit Trend
Full-year Guidance vs Actual
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
